TY  - JOUR
AU  - Kennedy, Oliver John
AU  - Kicinski, Michal
AU  - Valpione, Sara
AU  - Gandini, Sara
AU  - Suciu, Stefan
AU  - Blank, Christian U
AU  - Long, Georgina V
AU  - Atkinson, Victoria G
AU  - Dalle, Stéphane
AU  - Haydon, Andrew M
AU  - Meshcheryakov, Andrey
AU  - Khattak, Adnan
AU  - Carlino, Matteo S
AU  - Sandhu, Shahneen
AU  - Larkin, James
AU  - Puig, Susana
AU  - Ascierto, Paolo A
AU  - Rutkowski, Piotr
AU  - Schadendorf, Dirk
AU  - Boers-Sonderen, Marye
AU  - Di Giacomo, Anna Maria
AU  - van den Eertwegh, Alfonsus J M
AU  - Grob, Jean-Jacques
AU  - Gutzmer, Ralf
AU  - Jamal, Rahima
AU  - van Akkooi, Alexander C J
AU  - Robert, Caroline
AU  - Eggermont, Alexander M M
AU  - Lorigan, Paul
AU  - Mandala, Mario
TI  - Prognostic and predictive value of metformin in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma.
JO  - European journal of cancer
VL  - 189
SN  - 0014-2964
CY  - Amsterdam [u.a.]
PB  - Elsevier
M1  - DKFZ-2023-01106
SP  - 112900
PY  - 2023
N1  - 2023 Aug;189:112900
AB  - Metformin is a commonly prescribed and well-tolerated medication. In laboratory studies, metformin suppresses BRAF wild-type melanoma cells but accelerates the growth of BRAF-mutated cells. This study investigated the prognostic and predictive value of metformin, including with respect to BRAF mutation status, in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 randomised controlled trial.Patients with resected high-risk stage IIIA, IIIB, or IIIC melanoma received 200 mg of pembrolizumab (n = 514) or placebo (n = 505) every 3 weeks for twelve months. Pembrolizumab prolonged recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) at approximately 42 months median follow-up (Eggermont et al., TLO, 2021). Multivariable Cox regression was used to estimate associations of metformin with RFS and DMFS. Interaction terms were used to model effect modification by treatment and BRAF mutation.Fifty-four patients (0.5
KW  - BRAF (Other)
KW  - Immunomodulation (Other)
KW  - Immunotherapy (Other)
KW  - Melanoma (Other)
KW  - Metformin (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:37277264
DO  - DOI:10.1016/j.ejca.2023.04.016
UR  - https://inrepo02.dkfz.de/record/276423
ER  -